Breaking News Instant updates and real-time market news.

ADBE

Adobe

$127.01

4.66 (3.81%)

, TIF

Tiffany

$92.55

2.57 (2.86%)

16:14
03/17/17
03/17
16:14
03/17/17
16:14

On The Fly: Top stock stories for Friday

Stocks opened mixed but close to the flat line. The market moved in a narrow range throughout the session, as it has for most of the past two weeks. The tight trading range occurred despite the occasion of "quadruple witching," when stock index futures, stock index options, stock options, and single stock futures all expire on the same day. While trading stayed subdued for most of the session, a quiet day was enough to let the major averages each go out with gains on a weekly basis. ECONOMIC EVENTS: In the U.S., industrial production was flat in February with capacity utilization dipping to 75.4%. Consumer sentiment rose 1.3 points to 97.6 in the March preliminary print from the University of Michigan survey. The leading economic indicators rose 0.6% in February to 126.2, a record high level. Baker Hughes reported that the U.S. rig count was up 21 rigs from last week to 789 rigs. COMPANY NEWS: Shares of Adobe Systems (ADBE) gained 3.8% after the software company reported better than expected results for the quarter. The announcement sparked positive commentary from several Wall Street analysts, with many raising their price targets on the shares and Wunderlich upgrading the stock to Buy... Tiffany (TIF) also gained 2.7% after the jeweler and luxury goods retailer reported quarterly results that beat analysts' forecasts and gave an upbeat outlook for 2017... Meanwhile, ValueAct disclosed its purchase of 3M shares in Valeant Pharmaceuticals (VRX). This comes only a few days after Bill Ackman's Pershing Square sold its investment in the embattled drugmaker. MAJOR MOVERS: Among the notable gainers was AveXis (AVXS), which gained 0.87% after the company reported topline results from the Phase 1 trial of AVXS-101 in spinal muscular atrophy Type 1. Additionally, Five9 (FIVN) advanced over 7% after Pacific Crest analyst Brent Bracelin upgraded the stock to Overweight saying the company's cloud revenue could triple within five years. Among the noteworthy losers was Amgen (AMGN), which slid 6.4% after the company released the results of its 27,000-patient trial of cholesterol drug Repatha, which showed that it reduced the risk of heart attacks, strokes and other heart-related problems by 15% compared to a placebo, though investors seemed to be expecting a cardiovascular risk reduction of 20%-22%. Shares of others working on cholesterol drugs also moved lower, with The Medicines Co. (MDCO) falling 8% and Esperion Therapeutics (ESPR) plunging over 20%. Also lower was Caleres (CAL), which slipped 11.86% after the company posted weaker than expected fourth quarter adjusted earnings per share and guidance. INDEXES: The Dow fell 19.93, or 0.1%, to 20,914.62, the Nasdaq gained 24c, or 0.00%, to 5,901.00, and the S&P 500 declined 3.13, or 0.13%, to 2,378.25.

ADBE

Adobe

$127.01

4.66 (3.81%)

TIF

Tiffany

$92.55

2.57 (2.86%)

VRX

Valeant

$11.04

-0.16 (-1.43%)

AVXS

AveXis

$84.00

11.22 (15.42%)

FIVN

Five9

$18.02

1.19 (7.07%)

AMGN

Amgen

$168.41

-11.7 (-6.50%)

MDCO

The Medicines Co.

$48.38

-4.2 (-7.99%)

ESPR

Esperion

$23.67

-5.98 (-20.17%)

CAL

Caleres

$28.00

-3.655 (-11.55%)

  • 17

    Mar

  • 17

    Mar

  • 17

    Mar

  • 17

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 21

    Mar

  • 28

    Mar

  • 22

    Apr

  • 09

    May

  • 21

    May

  • 25

    May

  • 30

    May

  • 19

    Jul

  • 14

    Mar

ADBE Adobe
$127.01

4.66 (3.81%)

03/17/17
ADAM
03/17/17
NO CHANGE
Target $145
ADAM
Buy
Adobe price target raised to $145 from $125 at Canaccord
Canaccord analyst Richard Davis raised his price target on Adobe to $145 from $125 following Q1 results. The analyst believes the company has the right formula to organically expand its addressable market and cited its beat on all metrics with guidance suggesting continued strength into Q2. Davis said Adobe is the highest quality large-cap software name and reiterated his Buy rating on the shares.
03/17/17
03/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Adobe (ADBE) upgraded to Buy from Hold at Wunderlich with analyst Ryan Macdonald citing the company's better than expected first quarter results. The analyst raised his price target for the shares to $145 from $115. 2. L Brands (LB) upgraded to Outperform from Market Perform at FBR Capital with analyst Susan Anderson saying her survey work shows that Victoria Secret has not lost share over the past year and that same-store-sales will be better than expected in the second half of 2017. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at JMP Securities with analyst Liisa Bayko saying the company's triple combo data this year could expand its cystic fibrosis patient pool by greater than 50%. Positive triple combo data could make Vertex a takeover target, Bayko adds. 4. Dean Foods (DF) upgraded to Overweight from Neutral at JPMorgan with analyst Ken Goldman raising his estimates to reflect lower raw dairy costs. The outlook for Dean's largest input, Class I milk, has softened in recent months, Goldman tells investors in a research note. The analyst raised his price target for the shares to $22 from $20. 5. Barclays (BCS) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/17/17
BOFA
03/17/17
NO CHANGE
Target $160
BOFA
Buy
Adobe price target raised to $160 from $125 at BofA/Merrill
BofA Merrill Lynch analyst Kash Rangan called Adobe management conservative in maintaining their FY17 guidance after the company's strong "beat and raise" Q1 report, adding that he was surprised that net new Creative Cloud ARR and digital media ARR doubled year-over-year in the quarter. The analyst, who said the results give him more confidence in his long-term bull case, reiterates a Buy rating and raised his price target on Adobe to $160 from $125.
03/17/17
JMPS
03/17/17
NO CHANGE
JMPS
Adobe price target raised to $138 from $120 at JMP Securities
JMP Securities analyst Patrick Walravens raised his price target on Adobe as he believes that the company reported "strong" Q1 results. The analyst expects the company "to continue to drive profitable growth." He keeps an Outperform rating on the shares.
TIF Tiffany
$92.55

2.57 (2.86%)

03/15/17
JEFF
03/15/17
NO CHANGE
Target $102
JEFF
Buy
Jefferies sees catalysts for Tiffany, reiterates $102 price target
Jefferies analyst Randal Konik reiterates a Buy rating on shares of Tiffany with a $102 price target. The company has a strong positioning in a growing market, Konik tells investors in a research note. He believes improvements in fashion jewelry, easing tourism headwinds and more innovative marketing efforts present catalyst for the stock.
03/16/17
OPCO
03/16/17
NO CHANGE
Target $105
OPCO
Outperform
Tiffany price target raised to $105 from $87 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target for Tiffany to $105 from $87 as he is "increasingly optimistic" that fresh eyes within the company's senior ranks might bring an improved executional acumen and operating disciplines to the chain. The analyst reiterates an Outperform rating on the shares.
03/17/17
JEFF
03/17/17
NO CHANGE
Target $110
JEFF
Buy
Tiffany price target raised to $110 after Q4 results at Jefferies
Jefferies analyst Randal Konik raised his price target for Tiffany shares to $110 from $102 following the company's Q4 results. With sales accelerating, margins strengthening and product newness accelerating soon, the stock should move higher, Konik tells investors in a research note. He reiterates a Buy rating on Tiffany.
03/06/17
NOMU
03/06/17
NO CHANGE
NOMU
Tiffany has multiple potential positive catalysts, says Nomura
Nomura analyst Simeon Sigel says that Tiffany has multiple potential positive catalysts. The company can add 55-95 new stores in underpenetrated markets, which would increase its EPs by 50c-90c, according to the analyst. Tiffany could increase its EPS by 25c by obtaining its diamonds from more economical sources, and it could raise its EPS by another 25c by lowering its ad costs to the historical average, according to Sigel. Finally, Tiffany could raise its EPS another 35c-70c by taking steps to lower its tax rate below the current 35c level, wrote Sigel. The analyst raised his price target on the shares to $98 from $84 and keeps a Buy rating.
VRX Valeant
$11.04

-0.16 (-1.43%)

03/17/17
WELS
03/17/17
NO CHANGE
WELS
Underperform
Wells Fargo finds 'new significant negative' for Valeant
Wells Fargo analyst David Maris says the FDA's new guidance posted today on what is needed for generic Xifaxan is a "game changing development that makes it much easier for generics to show bioequivalence." The likelihood of Xifaxan generics entering the market in 2023 or earlier just "increased dramatically," Maris tells investors in a research note. He views today's guidance as a "new significant negative" for Valeant Pharmaceuticals. The stock is down 3c to $11.17 in late morning trading. Maris has an Underperform rating on Valeant with a $10-$13 price target range.
03/14/17
BMOC
03/14/17
NO CHANGE
Target $15
BMOC
Market Perform
Pershing exit sends 'poor signal' for Valeant future, says BMO Capital
BMO Capital analyst Gary Nachman believes the sale of Pershing Square's stake "sends a poor signal regarding the road ahead" for Valeant Pharmaceuticals. The analyst is surprised that Pershing decided to sell its entire investment. The timing is noteworthy since new management is just beginning to implement a number of its strategic initiatives, Nachman tells investors in a research note. The analyst cut his price target for Valeant shares to $15 from $19 and keeps a Market Perform rating on the name.
03/14/17
STFL
03/14/17
NO CHANGE
STFL
Valeant Pershing move to hurt sentiment but restructuring positive, says Stifel
After Valeant's top shareholder, Pershing Square, announced the offering of its 27.2M share stake in the company, Stifel analyst Annabel Samimy says that the transaction will hurt sentiment towards Valeant. However, the analyst continues to believe that the company's recent restructuring was an important, step that produced meaningful benefits for the company, and she says that it "remains committed to its $5B debt repayment target by early 2018." She keeps a Buy rating on the stock.
03/15/17
ADAM
03/15/17
NO CHANGE
Target $12
ADAM
Hold
Valeant price target lowered to $12 from $17 at Canaccord
Canaccord analyst Neil Maruoka lowered his price target on Valeant to $12 from $17 following the sale of Pershing Square's 27.2M share stake. The analyst stills sees the divesting of major assets as a challenge and the sale by Pershing as underscoring his concerns about the company's lower growth. Maruoka maintained his Hold rating on Valeant shares.
AVXS AveXis
$84.00

11.22 (15.42%)

03/17/17
GSCO
03/17/17
NO CHANGE
Target $108
GSCO
Buy
AveXis price target raised to $108 on higher confidence in AVXS-101 at Goldman
After AveXis (AVXS) reported results for its Phase 1 study of AVXS-101 in spinal muscular atrophy, Goldman Sachs analyst Salveen Richter said data for the treatment continues to impress and increased his probability of success for the drug to 85% from 65% previously. The analyst, who views AVXS-101 as a key competitive threat to Biogen (BIIB) and Ionis' (IONS) Spinraza as the potential first-line treatment for SMA, raised his price target on AveXis to $108 from $91 and keeps a Buy rating on the shares.
03/17/17
JEFF
03/17/17
NO CHANGE
Target $92
JEFF
Buy
AveXis price target raised to $92 from $79 at Jefferies
Jefferies analyst Biren Amin raised his price target for AveXis to $92 citing an improved outlook following final data from AVXS-101 in spinal muscular atrophy. All patients in both cohorts were event free at 13.6 months of age compared to 25% expected via natural history, Amin tells investors in a research note. The analyst reiterates a Buy rating on the shares.
12/27/16
STFL
12/27/16
NO CHANGE
Target $65
STFL
Hold
Spinraza launch could pose risk AveXis enrollment timelines, says Stifel
Stifel analyst Katherine Breedis noted that Biogen (BIIB) and partner Ionis (IONS) announced receipt of FDA approval of Spinraza for treatment of all types of Spinal Muscular Atrophy, or SMA, in-line with her expectations for a late 2016 or early 2017 U.S. approval with a "broad label." She anticipates it will garner rapid uptake as it becomes commercially available and believes Spinraza may be on the market as much as 6 months prior to the start of enrollment of AveXis' (AVXS) pivotal study of AVXS-101 in SMA Type 1 and the Phase 1 study of AVXS-101 in SMA Type 2, which could present risk to their enrollment timelines, she tells investors. Breedis maintains a Hold rating and $65 price target on Avexis shares, which are down about 6% to $50 in pre-market trading after its competitors approval news.
02/01/17
PIPR
02/01/17
NO CHANGE
PIPR
Piper call reveals 'extremely positive' commentary for Spinraza
Piper Jaffray analyst Joshua Schimmer says his call with a pediatric neuromuscular disease specialist yielded "extremely positive" commentary for the adoption of Biogen (BIIB) and Ionis Pharmaceuticals' (IONS) Spinraza. The specialist noted "explosive" growth in the spinal muscular atrophy population based on increased referral rates and return-to-clinic visits in anticipation of Spinraza, Schimmer tells investors in a research note. The analyst notes that the specialist also has interest in AveXis' (AVXS) gene therapy program, which she sees as encouraging and hopes is complementary to Spinraza. Regarding Sarepta's (SRPT) Exondys 51, the pediatric neuromuscular disease specialist said the launch has been slower with "reimbursement hurdles that reflect the less compelling efficacy data and controversial approval process for that product," Schimmer noted.
FIVN Five9
$18.02

1.19 (7.07%)

03/17/17
03/17/17
UPGRADE
Target $22

Overweight
Five9 upgraded to Overweight from Sector Weight at Pacific Crest
Pacific Crest analyst Brent Bracelin upgraded Five9 to Overweight with a $22 price target.
03/17/17
03/17/17
UPGRADE

Overweight
Five9 upgraded on cloud revenue outlook at Pacific Crest
As noted earlier, Pacific Crest upgraded Five9 to Overweight from Sector Weight. Analyst Brent Bracelin says that the company's cloud revenue could triple within five years. Target $22.
02/17/17
ROTH
02/17/17
NO CHANGE
Target $26
ROTH
Buy
Five9 price target raised to $26 from $22 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Five9 to $26 from $22 after the company's Q4 revenues and earnings both well-exceeded forecasts, and its pro forma net income turned positive for the first time in its history. While his forecasts call for a return to narrow losses until Q4, the analyst believes achieving this milestone a year ahead of his forecast should prove to be a "strong valuation catalyst." He reiterates a Buy rating on the shares.
01/13/17
ADAM
01/13/17
NO CHANGE
Target $20
ADAM
Buy
Five9 remains a top small-cap pick, says Canaccord
Canaccord analyst David Hynes said Five9 remains a top small cap pick for 2017 citing the company's own upward estimate revisions. The analyst said despite its growth rate its revenue multiples are only in line with the broader cloud group. He feels Five9 has the potential to be a top performing software name for the third straight year. Hynes reiterated his Buy rating and raised his price target to $20 from $18 on Five9 shares.
AMGN Amgen
$168.41

-11.7 (-6.50%)

03/17/17
PIPR
03/17/17
NO CHANGE
PIPR
Overweight
Amgen weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer recommends using today's weakness in shares of Amgen as a buying opportunity. The analyst believes Amgen can still turn Repatha into a $5B-plus product and he reiterates an Overweight rating on the shares.
03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
Overweight
Amgen data do not justify Medicines selloff, says JPMorgan
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
03/17/17
NEED
03/17/17
NO CHANGE
Target $25
NEED
Strong Buy
Needham calls Esperion selloff on Amgen data 'counter-intuitive'
Needham analyst Chad Messer believes the selloff in shares of Esperion Therapeutics (ESPR) based on Amgen's (AMGN) Repatha's data is "counter-intuitive." The fact that there was a statistically significant benefit confirms that LDL reductions prevent heart attacks and strokes, Messer tells investors in a research note. Bempedoic acid will likely be priced more in line with other oral cholesterol therapies, which makes the value debate for PCSK9 drugs a positive for Esperion, not a negative, the analyst contends. The analyst keeps a Buy rating on Esperion with a $25 price target.
03/17/17
OPCO
03/17/17
NO CHANGE
OPCO
Outperform
Amgen oversold on cholesterol data, says Oppenheimer
Oppenheimer analyst Leah Rush Cann says shares of Amgen are oversold after the FOURIER study of Repatha in patients with cardiovascular disease met its key endpoint. The risk reduction grew to 25% after one year on Repatha therapy, which is a "very important result," Cann tells investors in a research note. She believes the current stock price reflects little to no sales of Repatha through 2020. The analyst has an Outperform rating on Amgen, which is trading down 6% to $168.68.
MDCO The Medicines Co.
$48.38

-4.2 (-7.99%)

01/06/17
JEFF
01/06/17
NO CHANGE
Target $49
JEFF
Buy
Amgen ruling could mean 'blue skies' for Medicines Co., says Jefferies
Jefferies analyst Biren Amin raised his price target for The Medicines Co. (MDCO) to $49 from $43 after the District Court of Delaware ruled in favor of Amgen (AMGN) on the permanent injunction against Sanofi (SNY) and Regeneron's (RENG) Praluent. The ruling should have a favorable read-through to Medicines' inclisiran since the drug is "completely unique to the monoclonal antibody approach" and therefore would not infringe on Amgen's patents, Amin tells investors in a research note titled "Injunction on Sanofi/REGN's Praluent Could Mean Blue Skies for Inclisiran." The analyst raised his inclisiran peak sales estimates to $2.4B in 2027 and keeps a Buy rating on Medicines shares. The stock is up $2.98, or 8%, to $38.50 in pre-market trading.
03/17/17
LEER
03/17/17
NO CHANGE
LEER
Outperform
Leerink reiterates Outperform on Medicines after Amgen data
Leerink analyst Joseph Schwartz says Amgen's (AMGN) cholesterol lowering data this morning is less positive than expectations, in part due to management's bullishness ahead of the news. The analyst sees a "less than perfect read-through" to The Medicines Co. (MDCO), however, since the company is likely to study inclisiran in patients with more elevated cholesterol going forward. He reiterates an Outperform rating on Medicines shares. The stock is morning trading is down 21% to $41.38.
03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
The Medicines Co. selloff on Amgen data overdone, says JPMorgan
ESPR Esperion
$23.67

-5.98 (-20.17%)

03/09/17
FBCO
03/09/17
NO CHANGE
Target $29
FBCO
Underperform
Esperion price target raised to $29 from $12 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Esperion to $29 from $12 given quarterly results, increasing probability of success for bempedoic acid and assuming it can get approved in 2019 prior to the completion of its cardiovascular outcomes trial. The analyst maintains an Underperform rating on the shares given the strong move the stock has had and ahead of the American College of Cardiology Meeting.
03/13/17
SBSH
03/13/17
NO CHANGE
Target $39
SBSH
Buy
Esperion selloff Friday a buying opportunity, says Citi
Citi analyst Joel Beatty views Friday's selloff in shares of Esperion Therapeutics as a buying opportunity. Beatty says Reuters' report that President Trump is expected to nominate Scott Gottlieb to lead the FDA is consistent with his Buy thesis on Esperion. The analyst notes that Gottlieb favors deregulation. Beatty keeps a Buy rating on Esperion with a $39 price target.
03/03/17
STFL
03/03/17
NO CHANGE
Target $45
STFL
Buy
Esperion price target raised to $45 from $30 at Stifel
Stifel analyst Thomas Shrader sees Esperion (ESPR) receiving regulatory clarity on its ongoing CVOT trial in the next few months following recent comments from President Trump urging streamlined FDA approvals. Esperion has designed its Phase 3 program to include patients similar to those enrolled in the PCSK9 trials, suggesting that ETC-1002 will receive the same eventual label, said Shrader, who raised his price target on the stock to $45 from $30. He keeps a Buy rating on Esperion.
CAL Caleres
$28.00

-3.655 (-11.55%)

12/07/16
SUSQ
12/07/16
UPGRADE
Target $40
SUSQ
Positive
Caleres upgraded to Positive at Susquehanna
As reported previously, Susquehanna analyst Sam Poser upgraded Caleres to Positive from Neutral citing its exceptional margin growth in the Brand Portfolio and same store sales trends at Famous Footwear. The analyst also noted its inventory positioning and easy upcoming comps. Poser raised his price target to $40 from $25 on Caleres shares.
12/13/16
KING
12/13/16
DOWNGRADE
KING
Neutral
Caleres downgraded to Neutral from Buy at CL King
CL King downgraded Caleres to Neutral citing valuation.
03/03/17
MSCO
03/03/17
UPGRADE
MSCO
Overweight
Caleres upgraded to Overweight from Equal Weight at Morgan Stanley
03/03/17
03/03/17
UPGRADE
Target $37

Overweight
Caleres upgraded to Overweight on valuation, rising margins at Morgan Stanley
As previously reported, Morgan Stanley upgraded Caleres to Overweight from Equal Weight with a $37 price target. Analyst Jay Sole said Caleres has invested in warehousing and distribution since 2014 that should begin to drive EBIT margin expansion now, which is not reflected in valuation. Further, Allen Edmonds deal accretion should add at least 15c to FY17 and Sole's FY18 earnings forecast is now 6% above consensus.

TODAY'S FREE FLY STORIES

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$180.87

-0.99 (-0.54%)

17:47
11/22/17
11/22
17:47
11/22/17
17:47
Periodicals
Facebook tool to show users which content was Russian propaganda, says Bloomberg »

Facebook will add a tool…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$51.01

0.79 (1.57%)

17:24
11/22/17
11/22
17:24
11/22/17
17:24
Periodicals
CSX to charge more fees on customers that disregard shipping rules, Reuters says »

Starting on January 1st,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AYTU

Aytu BioScience

$3.03

0.4301 (16.54%)

17:10
11/22/17
11/22
17:10
11/22/17
17:10
Syndicate
Breaking Syndicate news story on Aytu BioScience »

Aytu BioScience files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPIX

ESSA Pharma

$0.27

0.0059 (2.27%)

17:09
11/22/17
11/22
17:09
11/22/17
17:09
Hot Stocks
ESSA Pharma to begin trading on TSX Venture Exchange »

ESSA Pharma is listing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRDN

Meridian Waste Solutions

$1.69

0.0101 (0.60%)

16:55
11/22/17
11/22
16:55
11/22/17
16:55
Syndicate
Breaking Syndicate news story on Meridian Waste Solutions »

Meridian Waste Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$161.62

-0.67 (-0.41%)

16:50
11/22/17
11/22
16:50
11/22/17
16:50
Syndicate
Breaking Syndicate news story on Air Products »

Air Products files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOT

Boot Barn

$13.49

-0.23 (-1.68%)

16:49
11/22/17
11/22
16:49
11/22/17
16:49
Syndicate
Breaking Syndicate news story on Boot Barn »

Boot Barn files $300M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$17.50

0.88 (5.29%)

, BCEI

Bonanza Creek

$32.14

0.46 (1.45%)

16:44
11/22/17
11/22
16:44
11/22/17
16:44
Hot Stocks
Icahn reports 13.51% stake in SandRidge Energy, intends to vote against Bonanza »

Icahn has read Fir Tree…

SD

SandRidge Energy

$17.50

0.88 (5.29%)

BCEI

Bonanza Creek

$32.14

0.46 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$17.50

0.88 (5.29%)

16:35
11/22/17
11/22
16:35
11/22/17
16:35
Hot Stocks
Icahn reports 13.51% stake in SandRidge Energy, intends to vote against Bonanza »

Icahn agrees with Fir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$28.43

0.32 (1.14%)

, AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

16:32
11/22/17
11/22
16:32
11/22/17
16:32
Hot Stocks
Symantec selects Amazon Web Services to deliver cloud security »

Amazon Web Services, an…

SYMC

Symantec

$28.43

0.32 (1.14%)

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

16:30
11/22/17
11/22
16:30
11/22/17
16:30
Options
Preliminary option volume of 13.6M today »

Preliminary option volume…

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

16:26
11/22/17
11/22
16:26
11/22/17
16:26
Hot Stocks
Amazon Web Services announces Amazon ML Solutions Lab program »

Amazon Web Services, Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

NRIM

Northrim BanCorp

$34.75

-0.25 (-0.71%)

16:22
11/22/17
11/22
16:22
11/22/17
16:22
Hot Stocks
Northrim BanCorp announces CFO transition »

Northrim BanCorp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

, CERN

Cerner

$70.03

3.35 (5.02%)

16:21
11/22/17
11/22
16:21
11/22/17
16:21
General news
On The Fly: Top stock stories for Wednesday »

Stocks opened in positive…

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

CERN

Cerner

$70.03

3.35 (5.02%)

HPE

HP Enterprise

$13.10

-1.02 (-7.22%)

HPQ

HP Inc.

$21.34

-1.12 (-4.99%)

DE

Deere

$145.25

6.02 (4.32%)

ROK

Rockwell Automation

$191.02

-2 (-1.04%)

EMR

Emerson

$61.88

1.53 (2.54%)

AKZOY

AkzoNobel

$31.04

0.475 (1.55%)

AXTA

Axalta Coating

$35.50

1.63 (4.81%)

GME

GameStop

$17.37

0.64 (3.83%)

GES

Guess

$15.62

-2.33 (-12.98%)

IRBT

iRobot

$68.50

-4.57 (-6.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 11

    Dec

  • 18

    Mar

CHMI

Cherry Hill Mortgage

$18.51

0.06 (0.33%)

16:21
11/22/17
11/22
16:21
11/22/17
16:21
Syndicate
Breaking Syndicate news story on Cherry Hill Mortgage »

Cherry Hill Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$49.75

-0.23 (-0.46%)

16:20
11/22/17
11/22
16:20
11/22/17
16:20
Hot Stocks
Nektar names new CRDO, CMO and CSO »

Nektar announced several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
11/22/17
11/22
16:20
11/22/17
16:20
Options
Closing CBOE SPX and VIX Index summary for November 22nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VGZ

Vista Gold

$0.68

0.0069 (1.03%)

16:18
11/22/17
11/22
16:18
11/22/17
16:18
Syndicate
Vista Gold enters $10M ATM agreement with H.C. Wainwright & Co. »

Vista Gold announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPX

GP Strategies

$23.50

-0.2 (-0.84%)

16:17
11/22/17
11/22
16:17
11/22/17
16:17
Hot Stocks
GP Strategies announces $10M share repurchase increase »

GP Strategies Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

$NSD

NASDAQ Market Internals

16:17
11/22/17
11/22
16:17
11/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.